Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Muthu, Valliappan ; Agarwal, Ritesh ; Rudramurthy, Shivaprakash Mandya ; Thangaraju, Deepak ; Shevkani, Manoj Radhakishan ; Patel, Atul K. ; Shastri, Prakash Srinivas ; Tayade, Ashwini ; Bhandari, Sudhir ; Gella, Vishwanath ; Savio, Jayanthi ; Madan, Surabhi ; Hallur, Vinay Kumar ; Maturu, Venkata Nagarjuna ; Srinivasan, Arjun ; Sethuraman, Nandini ; Sibia, Raminder Pal Singh ; Pujari, Sanjay ; Mehta, Ravindra ; Singhal, Tanu ; Saxena, Puneet ; Gupta, Varsha ; Nagvekar, Vasant ; Prayag, Parikshit ; Patel, Dharmesh ; Xess, Immaculata ; Savaj, Pratik ; Panda, Naresh ; Rajagopal, Gayathri Devi ; Parwani, Riya Sandeep ; Patel, Kamlesh ; Deshmukh, Anuradha ; Vyas, Aruna ; Sistla, Srinivas Kishore ; Padaki, Priyadarshini A ; Ramar, Dharshni ; Sarkar, Saurav ; Rachagulla, Bharani ; Vallandaramam, Pattabhiraman ; Premachandran, Krishna Prabha ; Pawar, Sunil ; Gugale, Piyush ; Hosamani, Pradeep ; Dutt, Sunil Narayan ; Nair, Satish ; Kalpakkam, Hariprasad ; Badhwar, Sanjiv ; Kompella, Kiran Kumar ; Singla, Nidhi ; Navlakhe, Milind ; Prayag, Amrita ; Singh, Gagandeep ; Dhakecha, Poorvesh ; Chakrabarti, Arunaloke
• Description:
  We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM.
• Subjects:
  Case-Control Studies COVID-19 Humans Mucorales Mucormycosis Multicenter Studies As Topic
• Source:
  Emerg Infect Dis. 2023; 29(1):8-19
• Pubmed ID:
  36573628
• Pubmed Central ID:
  PMC9796192
• Document Type:
  Journal Article
• Place as Subject:
  India
• Volume:
  29
• Issue:
  1
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:bd7d63ea0cc38dca4ec5dfd83d2ea0d1ae459a5dfe0c849d7bb0d75812257c4d
• Download URL:
  https://stacks.cdc.gov/view/cdc/127632/cdc_127632_DS1.pdf
• File Type:
  [PDF - 1.66 MB ]